期刊文献+

蔗糖铁对慢性射血分数中间值心力衰竭合并铁缺乏患者的疗效观察 被引量:2

Clinical observation of iron sucrose in patients with chronic heart failure with midrange ejection fraction and iron deficiency
下载PDF
导出
摘要 目的观察蔗糖铁对慢性射血分数中间值心力衰竭(HFmrEF)患者合并铁缺乏(ID)的疗效。方法90例慢性HFmrEF合并ID患者随机分为观察组和对照组,两组均给予常规抗心力衰竭治疗,观察组增加蔗糖铁静脉滴注。比较两组治疗半年后心功能级别、6 min步行距离、血红蛋白(Hb)、红细胞计数、N末端B型利钠肽原(NT-proBNP)水平、生活质量和不良事件情况。结果观察组治疗后心功能级别、NT-PROBNP水平、躯体状况评分、情绪状况评分、总体健康评分和因心力衰竭恶化住院率低于对照组(P<0.05),而6 min步行距离、Hb水平、红细胞计数高于对照组(P<0.05)。结论蔗糖铁可改善慢性HFmrEF合并ID患者的心功能、贫血、活动耐力和生活质量。 Objective To observe the clinical efficacy of iron sucrose in patients with chronic heart failure with midrange ejection fraction(HFmrEF)and iron deficiency(ID).Methods Ninety patients with chronic HFmrEF and ID were randomized to observation and control groups.In addition to routine anti-heart failure treatment,intravenous infusion of iron sucrose was added in observation group.Cardiac function,6-minute walking distance,levels of hemoglobin,erythrocytes and N-terminal pro-brain natriuretic peptide(NT-proBNP),quality of life and adverse events were compared between two groups after 0.5-year treatment.Results Compared with control group,heart function grading,NT-proBNP level,body condition score,emotional status score,overall health score and hospitalization rate due to heart failure deterioration were lower,while 6-minute walking distance,hemoglobin,erythrocytes were higher in observation group(P<0.05).Conclusion Iron sucrose can improve cardiac function,anemia,activity endurance,and quality of life in patients with chronic HFmrEF and ID.
作者 甄子英 黄俊豪 林子川 李劲维 ZHEN Zi-ying;HUANG Jun-hao;LIN Zi-chuan;LI Jin-wei(DepartmentⅠof Cardiology,Taishan People's Hospital,Taishan 529200,China)
出处 《广东医科大学学报》 2019年第5期563-566,共4页 Journal of Guangdong Medical University
基金 江门市卫生计生局科学技术研究项目(No.17A075)
关键词 射血分数中间值心力衰竭 蔗糖铁 铁缺乏 heart failure with midrange ejection fraction iron sucrose iron deficiency
  • 相关文献

参考文献10

二级参考文献40

  • 1沈卫峰.贫血与心血管疾病预后[J].上海医学,2008,31(10):685-686. 被引量:2
  • 2姜红,葛均波.心力衰竭流行病学特点[J].中国医学前沿杂志(电子版),2010,2(1):1-5. 被引量:90
  • 3Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnsis and Treatment of Chranic Heart Failure of the European Society. of Cardiology [J]. Eur Heart J, 2005, 26 (11): 1115-1140.
  • 4Cleland JG, Tendera M. Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study [J]. Eur heart J, 2006, 27 (19): 2338 - 2345.
  • 5Bergstrom A, Andersson B, Edner M, et al. Effect of carved itol on diastolic function in patients with diastolic heart failure and preserved systolic function Results of the Swedish Doppler echocardiographic study (SWEDIC) [J]. Eur J heart Fail, 2004, 6 (4): 453 - 461.
  • 6van der Meer P, Lipsic E, Westenbrink BD. et al. Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure [J]. Circulaion, 2005, 112 (12): 1743 -1747.
  • 7Tehrani F, Phan A, Morrissey R, et al. The prognostic value of anemia in patients with diastolic heart failure [J]. Tex Heart Inst J, 2009, 36 (3): 220 - 225.
  • 8Anand IS. Anemia and chronic heart failure implications and treatment options [J]. J Am Coli Cardiol, 2008, 52 (7): 501 - 511.
  • 9Guglin ME, Koul D. Cardiovascular effects of erythropoietin..anemia and beyond[J]. Cardiol Rev,2006,14(4),200- 204.
  • 10Van der Meer P, Lipsic E, Westenbrink BD, etal. Erythro- poietin resistance in patients with both heart and kidney failure [J]. Nat Clin Pract Nephrol, 2008, 4 (1) : 47.

共引文献4704

同被引文献22

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部